太惨了！新股上市7天跌6天，从55跌到39，股民：这是来卖公司的吧

Core Viewpoint - The newly listed stock, Beixin Life (688712), has experienced significant price declines shortly after its IPO, raising concerns about its performance and the potential for investor losses [1][11]. Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, being the first domestic company to offer both IVUS (Intravascular Ultrasound) and FFR (Fractional Flow Reserve) systems, thus filling a domestic gap and reducing reliance on imports [3]. Financial Performance - The company has reported continuous losses over the past three years, with revenues of 92.45 million yuan in 2022, projected to increase to 316.6 million yuan by 2024. However, net losses are expected to decrease from 290 million yuan in 2022 to 43.6 million yuan in 2024, totaling approximately 460 million yuan in losses over the three years [4]. Underwriting and Fundraising - The underwriting firm for Beixin Life is China International Capital Corporation (CICC), which planned to raise a total of 999 million yuan. The funds are allocated for the construction of a medical device industrialization base (382 million yuan), R&D projects (470 million yuan), and working capital (100 million yuan) [6]. Stock Performance - Beixin Life's stock opened at 49.64 yuan on its first trading day, marking a 183.33% increase, but has since fallen for six consecutive days, closing at 39.48 yuan, representing a decline of over 29% from its peak [8][9]. Investor Sentiment - Many investors who bought shares at the initial high are now facing significant losses, with sentiments expressed in forums indicating frustration and disappointment, suggesting that the IPO may have been more about capitalizing on the company than about genuine investment opportunities [11][13].